Basic Stats
| CIK | 1474835 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intellipharmaceutics International Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| June 14, 2024 |
Intellipharmaceutics Announces Downgrade to OTC Expert Market EXHIBIT 99.1 Intellipharmaceutics Announces Downgrade to OTC Expert Market TORONTO, Ontario, June 14, 2024 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSXV:IPCI.H) (“Intellipharmaceutics” or the “Company”) announced today that its common stock, currently traded on the OTCQB market, is expected to be downgraded to the OTC Expert Market on June 17, 2024 as a result of the Company not |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ....……..2.50 SEC FILE NUMBER 000-53805 NOTIFICATION OF LATE FILING CUSIP NUMBER 458173309 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Novemb |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| March 14, 2024 |
EXHIBIT 99.1 Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)- (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targe |
|
| March 7, 2024 |
Intellipharmaceutics Announces Cease Trade Order EXHIBIT 99.1 Intellipharmaceutics Announces Cease Trade Order TORONTO, Ontario, March 6, 2024 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| February 27, 2024 |
EXHIBIT 99.1 Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form TORONTO, Ontario, February 26, 2024 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| February 14, 2024 |
IPCI / Intellipharmaceutics International Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| February 9, 2024 |
Intellipharmaceutics International Inc. Announces Stock Option Grant EXHIBIT 99.1 Intellipharmaceutics International Inc. Announces Stock Option Grant TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)- ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage dr |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| February 6, 2024 |
Extension of Debenture Maturity Date EXHIBIT 4.84 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| February 6, 2024 |
EXHIBIT 4.87 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this exhibit. Execution Version TARO PHARMACEUTICALS INC. -and- INTELLIPHARMACEUTICS, CORP. LICENCE AND SUPPLY AGREEMENT Desvenlafaxine Extended-R |
|
| February 6, 2024 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Authorized and Outstanding Share Capital The following is a summary of material terms and provisions of the common shares (“Common Shares”) and other outstanding securities issued by Intellipharmaceutics International Inc. (the “Company”) as well as certain provisions of the articles of arrangement dated October 22, 2009, as amended (the “Articles”), and by-la |
|
| February 6, 2024 |
EXHIBIT 13.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2022 (the “Report”), I, Isa Odidi, the Chairman of the Board and Chief Executive Off |
|
| February 6, 2024 |
EXHIBIT 12.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amina Odidi, certify that: 1. I have reviewed this Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does not contain any untrue |
|
| February 6, 2024 |
EXHIBIT 4.88 PROMISSORY NOTE Principal: US$200,000.00 Dated: October 5, 2022 1. FOR VALUE RECEIVED, Intellipharmaceutics Corp. (the "Borrower"), promise to pay to or to the order of Ramnath Reddy. (the "Creditor") at any other place as the Creditor may, from time to time, designate by notice in writing to the Borrower, the principal sum of US$200,000.00 (the "Principal") with interest accruing on |
|
| February 6, 2024 |
Extension of Debenture Maturity Date EXHIBIT 4.86 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| February 6, 2024 |
EXHIBIT 12.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Isa Odidi, certify that: 1. I have reviewed this Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does not contain any untrue s |
|
| February 6, 2024 |
EXHIBIT 13.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2022(the “Report”), I, Amina Odidi, Acting Chief Financial Officer of the Company, c |
|
| February 6, 2024 |
Extension of Debenture Maturity Date EXHIBIT 4.85 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 10, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| February 6, 2024 |
EXHIBIT 4.89 PROMISSORY NOTE EXTENSION 1. THE PARTIES. This Promissory Note Extension Agreement (“Agreement”) made April 6, 2023 between: Borrower: Intellipharmaceutics Corp., with a mailing address of 30 Worcester Road, Toronto, ON M9W 5X2 (“Borrower”) and Lender: Actimus Inc, (“Lender”). HEREINAFTER the Borrower and Lender shall be referred together as the “Parties” and in consideration of the c |
|
| February 6, 2024 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent the use of our auditor’s report dated June 5, 2023 with respect to the consolidated financial statements of Intellipharmaceutics International Inc. and its subsidiaries as at November 30, 2022, 2021 and 2020 and for each of the years in the three-year period ended November 30, 2022, included in the Annual Report on th |
|
| January 12, 2024 |
EXHIBIT 99.1 Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)- ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and t |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| November 8, 2023 |
November 8, 2023 Frank Wyman United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D. |
|
| October 16, 2023 |
NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. |
|
| October 16, 2023 |
2023 Third Quarter Management Discussion and Analysis EXHIBIT 99.1 2023 Third Quarter Management Discussion and Analysis 1 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED AUGUST 31, 2023 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the August 31, 2023 condensed unaudited interim consolidated financial statements of Intellipharmaceut |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| October 16, 2023 |
Intellipharmaceutics Announces Third Quarter 2023 Results EXHIBIT 99.3 Intellipharmaceutics Announces Third Quarter 2023 Results Toronto, Ontario October 16, 2023 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today report |
|
| October 16, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended August 31, 2023. |
|
| October 16, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period en |
|
| October 6, 2023 |
EXHIBIT 99.2 Intellipharmaceutics International Inc. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND MANAGEMENT PROXY CIRCULAR 2023 Annual Meeting of Shareholders of Intellipharmaceutics International Inc. commencing at 11:30 a.m. (Toronto time) on September 14, 2023 at The National Club, 303 Bay Street, Toronto, Ontario August 1, 2023 - 1- NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GI |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pri |
|
| October 6, 2023 |
Intellipharmaceutics Reports Director Election Results EXHIBIT 99.1 Intellipharmaceutics Reports Director Election Results Toronto, Ontario, September 14, 2023, Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as r |
|
| October 6, 2023 |
EXHIBIT 99.3 August 15, 2023 Intellipharmaceutics International Inc. 30 Worcester Road Toronto, Ontario M9W 5X2 Confirmation of Mailing The following were sent by prepaid mail to all registered holders of security, not coded as “lost”, of Intellipharmaceutics International Inc. on August 15, 2023 Notice-and-Access Document Proxy Proxy Return Envelope Request for Financial Statements Please note th |
|
| October 6, 2023 |
EXHIBIT 99.1 Intellipharmaceutics International Inc. Annual Meeting of Shareholders Appointment of Proxyholder I/We, being holder(s) of common shares of Intellipharmaceutics International Inc. (the “Company”), hereby appoint of Dr. Amina Odidi, President and Chief Operating Officer of the Company, or, failing her, Patrick Yat, Vice-President, Chemistry and Analytical Services, of the Company of th |
|
| October 6, 2023 |
INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results EXHIBIT 99.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results This report is being filed pursuant to section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations and discloses the voting results for each matter voted upon at the annual meeting of shareholders of Intellipharmaceutics International Inc. (the “Corporation”) held on September 14, 2023 (the “Meeting”). |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of |
|
| October 6, 2023 |
EXHIBIT 99.4 SHAREHOLDERS FOR INTELLIPHARMACEUTICS INTERNATIONAL INC. NOTICE-AND-ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Intellipharmaceutics International Inc. (the “Company”) has decided to use the notice-and-access model for delivery of meeting materials to shareholders in connection with the Company’s annual meeting of shareholders to be held on September 14, |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period en |
|
| September 26, 2023 |
Intellipharmaceutics Announces First Quarter 2023 Results EXHIBIT 99.3 Intellipharmaceutics Announces First Quarter 2023 Results Toronto, Ontario June 5, 2023 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported t |
|
| September 26, 2023 |
2023 Second Quarter Management Discussion and Analysis EXHIBIT 99.1 2023 Second Quarter Management Discussion and Analysis 1 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the THREE and six MONTHS ENDED May 31, 2023 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the May 31, 2023 condensed unaudited interim consolidated financial statements of Intellipharmaceutics In |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| September 26, 2023 |
NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. February 28, 2023 i Intellipharmaceutics International Inc. February 28, 2023 Table of contents Condensed unaudited interim consolidated balance sheets 3 Condensed unaudited interim consolidated statements of operations and comprehensive loss 4 Condensed unaudited interim consolida |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended February 28, 202 |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended May 31, 2023. 2. |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period en |
|
| September 26, 2023 |
NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. May 31, 2023 Page 1 Intellipharmaceutics International Inc. May 31, 2023 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidated s |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| September 26, 2023 |
2023 First Quarter Management Discussion and Analysis EXHIBIT 99.1 2023 First Quarter Management Discussion and Analysis 1 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the THREE MONTHS ENDED February 28, 2023 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the February 28, 2023 condensed unaudited interim consolidated financial statements of Intellipharmaceutics I |
|
| September 26, 2023 |
Intellipharmaceutics Announces Second Quarter 2023 Results EXHIBIT 99.3 Intellipharmaceutics Announces Second Quarter 2023 Results Toronto, Ontario July 14, 2023 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| June 14, 2023 |
EXHIBIT 13.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2022(the “Report”), I, Amina Odidi, Acting Chief Financial Of |
|
| June 14, 2023 |
EXHIBIT 13.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2022 (the “Report”), I, Isa Odidi, the Chairman of the Board |
|
| June 14, 2023 |
Extension of Debenture Maturity Date EXHIBIT 4.85 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 10, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| June 14, 2023 |
Extension of Debenture Maturity Date EXHIBIT 4.84 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| June 14, 2023 |
EXHIBIT 12.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Isa Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does n |
|
| June 14, 2023 |
EXHIBIT 4.89 PROMISSORY NOTE EXTENSION 1. THE PARTIES. This Promissory Note Extension Agreement (“Agreement”) made April 6, 2023 between: Borrower: Intellipharmaceutics Corp., with a mailing address of 30 Worcester Road, Toronto, ON M9W 5X2 (“Borrower”) and Lender: Actimus Inc, (“Lender”). HEREINAFTER the Borrower and Lender shall be referred together as the “Parties” and in consideration of the c |
|
| June 14, 2023 |
EXHIBIT 12.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amina Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does |
|
| June 14, 2023 |
Extension of Debenture Maturity Date EXHIBIT 4.86 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| June 14, 2023 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Authorized and Outstanding Share Capital The following is a summary of material terms and provisions of the common shares (“Common Shares”) and other outstanding securities issued by Intellipharmaceutics International Inc. (the “Company”) as well as certain provisions of the articles of arrangement dated October 22, 2009, as amended (the “Articles”), and by-la |
|
| June 14, 2023 |
EXHIBIT 4.88 PROMISSORY NOTE Principal: US$200,000.00 Dated: October 5, 2022 1. FOR VALUE RECEIVED, Intellipharmaceutics Corp. (the "Borrower"), promise to pay to or to the order of Ramnath Reddy. (the "Creditor") at any other place as the Creditor may, from time to time, designate by notice in writing to the Borrower, the principal sum of US$200,000.00 (the "Principal") with interest accruing on |
|
| June 14, 2023 |
EXHIBIT 4.87 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this exhibit. Execution Version TARO PHARMACEUTICALS INC. -and- INTELLIPHARMACEUTICS, CORP. LICENCE AND SUPPLY AGREEMENT Desvenlafaxine Extended-R |
|
| June 14, 2023 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference of our auditor’s report dated June 05, 2023 with respect to the consolidated financial statements of Intellipharmaceutics International Inc. and its subsidiaries as at November 30, 2022, 2021 and 2020 and for each of the years in the three year period ended November 30, 2022, included |
|
| February 14, 2023 |
IPCI / Intellipharmaceutics International Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ipcif123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTELLIPHARMACEUTICS INTERNATIONAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 458173101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| October 14, 2022 |
See accompanying notes to condensed unaudited interim consolidated financial statements EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. August 31, 2022 Intellipharmaceutics International Inc. August 31, 2022 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidated st |
|
| October 14, 2022 |
Intellipharmaceutics Announces Third Quarter 2022 Results EXHIBIT 99.3 Intellipharmaceutics Announces Third Quarter 2022 Results Toronto, Ontario October 14, 2022 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today report |
|
| October 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the ?interim filings?) of Intellipharmaceutics International Inc. (the ?issuer?) for the interim period en |
|
| October 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the ?interim filings?) of Intellipharmaceutics International Inc. (the ?issuer?) for the interim period ended August 31, 2022. |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant?s name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| October 14, 2022 |
EXHIBIT 99.1 2022 Third Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the THREE and NINE MONTHS ENDED AUGUST 31, 2022 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the August 31, 2022 condensed unaudited interim consolidated financial statements of Intellipharmaceutic |
|
| July 21, 2022 |
2022 Second Quarter Management Discussion and Analysis EXHIBIT 99.1 2022 Second Quarter Management Discussion and Analysis 1 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the THREE and six MONTHS ENDED May 31, 2022 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the May 31, 2022 condensed unaudited interim consolidated financial statements of Intellipharmaceutics In |
|
| July 21, 2022 |
Intellipharmaceutics Announces Second Quarter 2022 Results EXHIBIT 99.3 Intellipharmaceutics Announces Second Quarter 2022 Results Toronto, Ontario July 21, 2022 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| July 21, 2022 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. May 31, 2022 Intellipharmaceutics International Inc. May 31, 2022 Table of contents Condensed unaudited interim consolidated balance sheets 3 Condensed unaudited interim consolidated statements of operations and comprehensive loss 4 Condensed unaudited interim consolidated statemen |
|
| July 21, 2022 |
x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant?s name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pri |
|
| July 21, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the ?interim filings?) of Intellipharmaceutics International Inc. (the ?issuer?) for the interim period en |
|
| July 21, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the ?interim filings?) of Intellipharmaceutics International Inc. (the ?issuer?) for the interim period ended May 31, 2022. 2. |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| July 15, 2022 |
EXHIBIT 99.1 Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022 TORONTO, Ontario, July 15, 2022 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and ge |
|
| May 27, 2022 |
INTELLIPHARMACEUTICS INTERNATIONAL INC. ANNUAL MEETING OF SHAREHOLDERS May 27, 2022 VOTING RESULTS EXHIBIT 99.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. ANNUAL MEETING OF SHAREHOLDERS May 27, 2022 VOTING RESULTS Resolution #1: The Chairman declared that the shareholders ratified the ratified the Election of Directors for all nominees listed below: Nominees For % Withheld % Dr. Isa Odidi 12,104,193 98.82% 144,707 1.18% Dr. Amina Odidi 12,124,250 98.98% 124,650 1.02% Bahadur Madhani 12,061,655 98. |
|
| May 27, 2022 |
Intellipharmaceutics Reports Director Election Results EXHIBIT 99.1 Intellipharmaceutics Reports Director Election Results Toronto, Ontario, May 27, 2022, Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as require |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princi |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.81 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.74 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.78 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.75 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| May 9, 2022 |
EXHIBIT 13.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the ?Company?) on Form 20-F for the period ending November 30, 2021 (the ?Report?), I, Isa Odidi, the Chairman of the Board |
|
| May 9, 2022 |
EXHIBIT 12.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Isa Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does n |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.77 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.73 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| May 9, 2022 |
EXHIBIT 12.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amina Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.79 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.82 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| May 9, 2022 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement No(s). 333-172796 and 333-218297 on Form F-3, and in Registration Statement No(s). 333-226239, 333-227448 and 333-227794 on Form F-1, of our auditor?s report dated February 28, 2022, relating to the consolidated financial statements of Intellipharmaceutics In |
|
| May 9, 2022 |
EXHIBIT 13.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the ?Company?) on Form 20-F for the period ending November 30, 2021 (the ?Report?), I, Amina Odidi, Acting Chief Financial O |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.71 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.72 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.83 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| May 9, 2022 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Authorized and Outstanding Share Capital The following is a summary of material terms and provisions of the common shares (?Common Shares?) and other outstanding securities issued by Intellipharmaceutics International Inc. (the ?Company?) as well as certain provisions of the articles of arrangement dated October 22, 2009, as amended (the ?Articles?), and by-la |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.69 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.80 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.76 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| May 9, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.70 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 29, 2022 |
EX-99.4 5 ex994.htm EXHIBIT 99.4 EXHIBIT 99.4 |
|
| April 29, 2022 |
EXHIBIT 99.5 SHAREHOLDERS FOR INTELLIPHARMACEUTICS INTERNATIONAL INC. NOTICE-AND-ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Intellipharmaceutics International Inc. (the ?Company?) has decided to use the notice-and-access model for delivery of meeting materials to shareholders in connection with the Company?s annual meeting of shareholders to be held on May 27, 2022 |
|
| April 29, 2022 |
EXHIBIT 99.2 Intellipharmaceutics International Inc. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND MANAGEMENT PROXY CIRCULAR 2022 Annual Meeting of Shareholders of Intellipharmaceutics International Inc. commencing at 11:30 a.m. (Toronto time) on May 27, 2022 at The National Club, 303 Bay Street, Toronto, Ontario April 12, 2022 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT th |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| April 29, 2022 |
EX-99.3 4 ex993.htm EXHIBIT 99.3 EXHIBIT 99.3 April 27, 2022 Intellipharmaceutics International Inc. 30 Worcester Road Toronto, Ontario M9W 5X2 Confirmation of Mailing The following were sent by prepaid mail to all registered holders of security, not coded as “lost”, of Intellipharmaceutics International Inc. on April 27, 2022 Notice-and-Access Document Proxy Proxy Return Envelope Request for Fina |
|
| April 29, 2022 |
Exhibit 99.1 Intellipharmaceutics International Inc. Annual & Special Meeting of Shareholders Appointment of Proxyholder I/We, being holder(s) of common shares of Intellipharmaceutics International Inc. (the ?Company?), hereby appoint of Dr. Amina Odidi, President and Chief Operating Officer of the Company, or, failing her, Patrick Yat, Vice-President, Chemistry and Analytical Services, of the Com |
|
| April 14, 2022 |
Intellipharmaceutics Announces First Quarter 2022 Results EXHIBIT 99.3 Intellipharmaceutics Announces First Quarter 2022 Results Toronto, Ontario April 14, 2022 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| April 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended February 28, 202 |
|
| April 14, 2022 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. February 28, 2022 Intellipharmaceutics International Inc. February 28, 2022 Table of contents Condensed unaudited interim consolidated balance sheets 3 Condensed unaudited interim consolidated statements of operations and comprehensive loss 4 Condensed unaudited interim consolidate |
|
| April 14, 2022 |
EXHIBIT 99.1 2022 First Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2022 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the February 28, 2022 condensed unaudited interim consolidated financial statements of Intellipharmaceutics Int |
|
| April 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, President/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period en |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EX-4.77 10 ipiiex477.htm EX - 4.77 EXHIBIT 4.77 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.71 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.83 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| April 1, 2022 |
EXHIBIT 13.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2018 (the “Report”), I, Isa Odidi, the Chairman of the Board |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.76 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| April 1, 2022 |
EXHIBIT 13.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Amendment No. 1 to the Annual Report of Intellipharmaceutics International Inc. (the “Company”) on Form 20-F for the period ending November 30, 2018 (the “Report”), I, Amina Odidi, Acting Chief Financial O |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.81 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.69 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.74 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| April 1, 2022 |
EXHIBIT 12.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amina Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.73 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.72 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.70 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated May 1, 2019, for a face amount of US $1,050,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current Matu |
|
| April 1, 2022 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement No(s). 333-172796 and 333-218297 on Form F-3, and in Registration Statement No(s). 333-226239, 333-227448 and 333-227794 on Form F-1, of our auditor?s report dated February 28, 2022, relating to the consolidated financial statements of Intellipharmaceutics In |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.80 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.75 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.82 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| April 1, 2022 |
EXHIBIT 12.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Isa Odidi, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does n |
|
| April 1, 2022 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Authorized and Outstanding Share Capital The following is a summary of material terms and provisions of the common shares (?Common Shares?) and other outstanding securities issued by Intellipharmaceutics International Inc. (the ?Company?) as well as certain provisions of the articles of arrangement dated October 22, 2009, as amended (the ?Articles?), and by-la |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.78 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated September 1, 2018 with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debe |
|
| April 1, 2022 |
Extension of Debenture Maturity Date EXHIBIT 4.79 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the "Company") RE: Debenture dated November 15, 2019, for a face amount of US $250,000 issued by the Company to Isa Odidi and Amina Odidi (the "Debenture") and the Maturity Date (as defined in the Debenture and as extended from time to time) of such Debenture The undersigned hereby agree that the current |
|
| March 1, 2022 |
Intellipharmaceutics Announces Fiscal Year 2021 Results EXHIBIT 99.3 Intellipharmaceutics Announces Fiscal Year 2021 Results Toronto, Ontario February 28, 2022 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reporte |
|
| March 1, 2022 |
ANNUAL INFORMATION FORM (for the fiscal year ended November 30, 2021) INTELLIPHARMACEUTICS INTERNATIONAL INC. |
|
| March 1, 2022 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Amina Odidi Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, |
|
| March 1, 2022 |
EXHIBIT 99.2 Consolidated financial statements of Intellipharmaceutics International Inc. November 30, 2021, 2020 and 2019 Intellipharmaceutics International Inc. November 30, 2021, 2020 and 2019 Table of contents Report of Independent Registered Public Accounting Firm 2 Consolidated balance sheets 3 Consolidated statements of operations and comprehensive loss 4 Consolidated statements of sharehol |
|
| March 1, 2022 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE EX-99.4 6 ipiiex994.htm CEO EXHIBIT 99.4 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by referenc |
|
| March 1, 2022 |
EXHIBIT 99.2 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the |
|
| March 1, 2022 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE EX-99.3 4 form52-109f1cfo.htm EXHIBIT 99.3 EXHIBIT 99.3 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Dr. Amina Odidi, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant’s name into English) 30 WORCESTER ROAD TORONTO, ON M9W 5X2 (Address of princi |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| March 1, 2022 |
EXHIBIT 99.1 2021 Year end Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the November 30, 2021condensed audited consolidated financial statements of Intellipharmaceutics International Inc. The cond |
|
| February 15, 2022 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
EX-99.A 2 d319957dex99a.htm EX-99.A Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Shares, of Intellipharmaceutics International Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 4, 2022 |
Intellipharmaceutics Reports Director Election Results EX-99.1 2 ex991pressrelease.htm EXHIBIT 99.1 EXHIBIT 99.1 Intellipharmaceutics Reports Director Election Results Toronto, Ontario, February 4, 2022, Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| February 4, 2022 |
INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results EX-99.2 3 ex992votingresults.htm EXHIBIT 99.2 EXHIBIT 99.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results This report is being filed pursuant to section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations and discloses the voting results for each matter voted upon at the annual meeting of shareholders of Intellipharmaceutics International Inc. (the “Corporation |
|
| January 13, 2022 |
6-K 1 form6-k.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORO |
|
| January 13, 2022 |
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead EXHIBIT 99.1 Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead Toronto, Ontario, January 13, 2022, Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral soli |
|
| January 6, 2022 |
EXHIBIT 99.5 SHAREHOLDERS FOR INTELLIPHARMACEUTICS INTERNATIONAL INC. NOTICE-AND-ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Intellipharmaceutics International Inc. (the “Company”) has decided to use the notice-and-access model for delivery of meeting materials to shareholders in connection with the Company’s annual meeting of shareholders to be held on February 4, 2 |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| January 6, 2022 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Intellipharmaceutics International Inc. Annual & Special Meeting of Shareholders Appointment of Proxyholder I/We, being holder(s) of common shares of Intellipharmaceutics International Inc. (the “Company”), hereby appoint: Dr. Isa Odidi, Chairman of the Board and Chief Executive Officer of the Company, or, failing him, Dr. Amina Odidi, President and Ch |
|
| January 6, 2022 |
EXHIBIT 99.4 |
|
| January 6, 2022 |
EXHIBIT 99.2 Intellipharmaceutics International Inc. NOTICE OF 2021 ANNUAL MEETING OF SHAREHOLDERS AND MANAGEMENT PROXY CIRCULAR Annual Meeting of Shareholders of Intellipharmaceutics International Inc. commencing at 11:30 a.m. (Toronto time) on February 4, 2022 at The National Club, 303 Bay Street, Toronto, Ontario December 21, 2021 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN |
|
| January 6, 2022 |
EXHIBIT 99.3 January 6, 2022 Intellipharmaceutics International Inc. 30 Worcester Road Toronto, Ontario M9W 5X2 Confirmation of Mailing The following were sent by prepaid mail to all registered holders of security, not coded as ?lost?, of Intellipharmaceutics International Inc. on January 5, 2022 Notice-and-Access Document Proxy Proxy Return Envelope Please note that: ? We have coded registered se |
|
| December 23, 2021 |
Intellipharmaceutics Comments on Recent Trading Activity EXHIBIT 99.1 Intellipharmaceutics Comments on Recent Trading Activity TORONTO, Ontario December 22, 2021 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is issuing thi |
|
| December 23, 2021 |
6-K 1 form6-k.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TOR |
|
| October 15, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended August 31, 2021 |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| October 15, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| October 15, 2021 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. August 31, 2021 Intellipharmaceutics International Inc. August 31, 2021 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidated st |
|
| October 15, 2021 |
Intellipharmaceutics Announces Third Quarter 2021 Results EXHIBIT 99.3 Intellipharmaceutics Announces Third Quarter 2021 Results Toronto, Ontario July 15, 2021 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| October 15, 2021 |
EXHIBIT 99.1 2021 Third Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED AUGUST 31, 2021 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the August 31, 2021 condensed unaudited interim consolidated financial statements of Intellipharmaceutic |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| July 15, 2021 |
EX-99.2 3 ex992.htm ADDITIONAL EXHIBITS EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. May 31, 2021 Intellipharmaceutics International Inc. May 31, 2021 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed |
|
| July 15, 2021 |
Intellipharmaceutics Announces Second Quarter 2021 Results EX-99.3 4 ex993.htm ADDITIONAL EXHIBITS EXHIBIT 99.3 Intellipharmaceutics Announces Second Quarter 2021 Results Toronto, Ontario July 15, 2021 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release |
|
| July 15, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| July 15, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 ex994ceo.htm ADDITIONAL EXHIBITS EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") fo |
|
| July 15, 2021 |
EX-99.1 2 ex991.htm ADDITIONAL EXHIBITS EXHIBIT 99.1 2021 Second Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED MAY 31, 2021 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the May 31, 2021 condensed unaudited interim consolidated financial |
|
| April 22, 2021 |
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement EXHIBIT 99.1 Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement Toronto, Ontario, April 22, 2021 - Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral s |
|
| April 22, 2021 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| April 14, 2021 |
Intellipharmaceutics Announces First Quarter 2021 Results EXHIBIT 99.3 Intellipharmaceutics Announces First Quarter 2021 Results Toronto, Ontario April 14, 2021 ? Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (?Intellipharmaceutics? or the ?Company?), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| April 14, 2021 |
EXHIBIT 99.1 2021 First Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2021 The following Management Discussion and Analysis (?MD&A?) should be read in conjunction with the February 28, 2021 condensed unaudited interim consolidated financial statements of Intellipharmaceutics Int |
|
| April 14, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended February 28, 202 |
|
| April 14, 2021 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| April 14, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| April 14, 2021 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. February 28, 2021 Intellipharmaceutics International Inc. February 28, 2021 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidate |
|
| March 31, 2021 |
EXHIBIT 4.23 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 31, 2021 |
Extension of Debenture Maturity Date EXHIBIT 4.21 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 31, 2021 |
Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange EXHIBIT 12.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amina Odidi, certify that: 1. I have reviewed this Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does not contain any untrue |
|
| March 31, 2021 |
EXHIBIT 4.25 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F [] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE |
|
| March 31, 2021 |
Exhibit 13.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Intellipharmaceutics International Inc. (the ?Company?) on Form 20-F for the period ending November 30, 2020 (the ?Report?), I, Isa Odidi, the Chairman of the Board and Chief Executive Off |
|
| March 31, 2021 |
Exhibit 13.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Intellipharmaceutics International Inc. (the ?Company?) on Form 20-F for the period ending November 30, 2020 (the ?Report?), I, Amina Odidi, Acting Chief Financial Officer of the Company, |
|
| March 31, 2021 |
EXHIBIT 4.55 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debenture |
|
| March 31, 2021 |
EX-4.66 12 ex466.htm EXHIBIT 4.66 EXHIBIT 4.66 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the “Company”) RE: Debenture dated November 15, 2019, with an original face amount of US$250,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the “Debenture”) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree |
|
| March 31, 2021 |
EXHIBIT 4.68 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated November 15, 2019, with an original face amount of US$250,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| March 31, 2021 |
EXHIBIT 4.22 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 31, 2021 |
EXHIBIT 4.64 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated November 15, 2019, with an original face amount of US$250,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| March 31, 2021 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Authorized and Outstanding Share Capital The following is a summary of material terms and provisions of the common shares (?Common Shares?) and other outstanding securities issued by Intellipharmaceutics International Inc. (the ?Company?) as well as certain provisions of the articles of arrangement dated October 22, 2009, as amended (the ?Articles?), and by-la |
|
| March 31, 2021 |
Consent of Independent Registered Public Accounting Firm (MNP LLP) EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement No(s). 333-172796 and 333-218297 on Form F-3, and in Registration Statement No(s). 333-226239, 333-227448 and 333-227794 on Form F-1, of our auditor?s report dated February 28, 2021, relating to the consolidated financial statements of Intellipharmaceutics In |
|
| March 31, 2021 |
EXHIBIT 4.65 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated November 15, 2019, with an original face amount of US$250,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| March 31, 2021 |
EXHIBIT 4.56 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$500,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debenture |
|
| March 31, 2021 |
EXHIBIT 4.69 LEASE DEFAULT AGREEMENT THIS AGREEMENT made as of the 20th day of August, 2020. B E T W E E N: Finley W. Mclachlan Properties Inc. and Dufferin Lumber and Supply Company Limited (collectively herein the ?Landlord?) OF THE FIRST PART -and Intellipharmaceutics Corp. (herein the ?Tenant?) OF THE SECOND PART WHEREAS the: A. Landlord and the Tenant are parties to lease (the ?Lease?) for a |
|
| March 31, 2021 |
EXHIBIT 4.67 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated November 15, 2019, with an original face amount of US$250,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Deb |
|
| March 31, 2021 |
EXHIBIT 4.24 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the ?Company?) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the ?Debenture?) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 31, 2021 |
Exhibit 12.1 INTELLIPHARMACEUTICS INTERNATIONAL INC. CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Isa Odidi, certify that: 1. I have reviewed this Annual Report on Form 20-F of Intellipharmaceutics International Inc.; 2. Based on my knowledge, this report does not contain any untrue s |
|
| March 1, 2021 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE EXHIBIT 99.3 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Dr. Amina Odidi, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (toget |
|
| March 1, 2021 |
EXHIBIT 99.2 Consolidated financial statements of Intellipharmaceutics International Inc. November 30, 2020, 2019 and 2018 Intellipharmaceutics International Inc. November 30, 2020, 2019 and 2018 Table of contents Report of Independent Registered Public Accounting Firm 1 Consolidated balance sheets 2 Consolidated statements of operations and comprehensive loss 3 Consolidated statements of sharehol |
|
| March 1, 2021 |
EXHIBIT 99.1 2020 Year end Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEAR ENDED NOVEMBER 30,2020 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the November 30, 2020 consolidated financial statements of Intellipharmaceutics International Inc. The consolidated financial |
|
| March 1, 2021 |
EXHIBIT 99.1 ANNUAL INFORMATION FORM (for the fiscal year ended November 30, 2020) INTELLIPHARMACEUTICS INTERNATIONAL INC. 30 Worcester Road Toronto, Ontario M9W 5X2 CANADA February 28, 2021 TABLE OF CONTENTS Page REFERENCE INFORMATION 1 FORWARD-LOOKING INFORMATION 1 TRADEMARKS 2 CORPORATE STRUCTURE 3 GENERAL DEVELOPMENT OF THE BUSINESS 4 CODE OF CONDUCT 27 RISK FACTORS 27 DIVIDENDS 55 CAPITAL STR |
|
| March 1, 2021 |
Intellipharmaceutics Announces Fiscal Year 2020 Results EX-99.3 5 ex993.htm EXHIBIT 99.3 EXHIBIT 99.3 Intellipharmaceutics Announces Fiscal Year 2020 Results Toronto, Ontario March 1, 2021 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral soli |
|
| March 1, 2021 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant?s name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| March 1, 2021 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| March 1, 2021 |
EXHIBIT 99.2 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 23, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| December 23, 2020 |
INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results EXHIBIT 99.2 INTELLIPHARMACEUTICS INTERNATIONAL INC. Report of Voting Results This report is being filed pursuant to section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations and discloses the voting results for each matter voted upon at the annual meeting of shareholders of Intellipharmaceutics International Inc. (the “Corporation”) held on December 23, 2020 (the “Meeting”). |
|
| December 23, 2020 |
Intellipharmaceutics Reports Director Election Results EXHIBIT 99.1 Intellipharmaceutics Reports Director Election Results Toronto, Ontario, December 23, 2020, Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as re |
|
| December 15, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| December 15, 2020 |
EXHIBIT 99.1 Intellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020 TORONTO, Ontario December 15, 2020 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic contro |
|
| November 24, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of p |
|
| November 24, 2020 |
EXHIBIT 99.5 SHAREHOLDERS FOR INTELLIPHARMACEUTICS INTERNATIONAL INC. NOTICE-AND-ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Intellipharmaceutics International Inc. (the “Company”) has decided to use the notice-and-access model for delivery of meeting materials to shareholders in connection with the Company’s annual meeting of shareholders to be held on December 23, |
|
| November 24, 2020 |
EXHIBIT 99.4 |
|
| November 24, 2020 |
EXHIBIT 99.3 November 23, 2020 Intellipharmaceutics International Inc. 30 Worcester Road Toronto, Ontario M9W 5X2 Confirmation of Mailing The following were sent by prepaid mail to all registered holders of security, not coded as “lost”, of Intellipharmaceutics International Inc. on November 20, 2020 Notice-and-Access Document Proxy Proxy Return Envelope Please note that: ● We have coded registere |
|
| November 24, 2020 |
Exhibit 99.1 Intellipharmaceutics International Inc. Annual & Special Meeting of Shareholders Appointment of Proxyholder I/We, being holder(s) of common shares of Intellipharmaceutics International Inc. (the “Company”), hereby appoint: Dr. Isa Odidi, Chairman of the Board and Chief Executive Officer of the Company, or, failing him, Dr. Amina Odidi, President and Chief Operating Officer of the Comp |
|
| November 24, 2020 |
EXHIBIT 99.2 Intellipharmaceutics International Inc. NOTICE OF 2020 ANNUAL MEETING OF SHAREHOLDERS AND MANAGEMENT PROXY CIRCULAR Annual Meeting of Shareholders of Intellipharmaceutics International Inc. commencing at 11:30 a.m. (Toronto time) on December 23, 2020 at Holiday Inn Oakville Centre, 590 Argus Road, Oakville, Ontario .. November 9, 2020 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE IS |
|
| October 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended August 31, 2020 |
|
| October 15, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of pr |
|
| October 15, 2020 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. August 31, 2020 Intellipharmaceutics International Inc. August 31, 2020 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive income (loss) 3 Condensed unaudited interim consol |
|
| October 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| October 15, 2020 |
Intellipharmaceutics Announces Third Quarter 2020 Results EXHIBIT 99.3 Intellipharmaceutics Announces Third Quarter 2020 Results Toronto, Ontario October 15, 2020 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today report |
|
| October 15, 2020 |
EXHIBIT 99.1 2020 Third Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED AUGUST 31, 2020 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the August 31, 2020 condensed unaudited interim consolidated financial statements of Intellipharmaceutic |
|
| July 15, 2020 |
Intellipharmaceutics Announces Second Quarter 2020 Results EXHIBIT 99.3 Intellipharmaceutics Announces Second Quarter 2020 Results Toronto, Ontario July 15, 2020 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported |
|
| July 15, 2020 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. May 31, 2020 Intellipharmaceutics International Inc. May 31, 2020 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidated statemen |
|
| July 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| July 15, 2020 |
EXHIBIT 99.1 2020 Second Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED MAY 31, 2020 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the May 31, 2020 condensed unaudited interim consolidated financial statements of Intellipharmaceutics Inte |
|
| July 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended May 31, 2020 . 2 |
|
| July 15, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| July 2, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princ |
|
| July 2, 2020 |
EXHIBIT 99.1 Intellipharmaceutics Announces That The Company And Purdue Pharma L.P. et al Have Entered Into A Stipulated Dismissal Agreement To Terminate Purdue Patent Litigation, Subject To Court Approval TORONTO, Ontario July 2, 2020 - Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the researc |
|
| May 29, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Amina Odidi, Presideent/COO, Acting Chief Financial Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period e |
|
| May 29, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Dr. Isa Odidi, Chief Executive Officer, of Intellipharmaceutics International Inc., certify the following 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the "interim filings") of Intellipharmaceutics International Inc. (the "issuer") for the interim period ended February 29, 202 |
|
| May 29, 2020 |
Intellipharmaceutics Announces First Quarter 2020 Results EXHIBIT 99.3 Intellipharmaceutics Announces First Quarter 2020 Results Toronto, Ontario May 29, 2020 – Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported t |
|
| May 29, 2020 |
Current Report of Foreign Issuer - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of princi |
|
| May 29, 2020 |
EXHIBIT 99.2 Condensed unaudited interim consolidated financial statements of Intellipharmaceutics International Inc. February 29, 2020 Intellipharmaceutics International Inc. February 29, 2020 Table of contents Condensed unaudited interim consolidated balance sheets 2 Condensed unaudited interim consolidated statements of operations and comprehensive loss 3 Condensed unaudited interim consolidate |
|
| May 29, 2020 |
EXHIBIT 99.1 2020 First Quarter Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED FEBRUARY 29, 2020 The following Management Discussion and Analysis (“MD&A”) should be read in conjunction with the February 29, 2020 condensed unaudited interim consolidated financial statements of Intellipharmaceutics Int |
|
| April 10, 2020 |
Intellipharmaceutics Provides Timing of First Quarter 2020 Results EXHIBIT 99.1 Intellipharmaceutics Provides Timing of First Quarter 2020 Results TORONTO, Ontario April 9, 2020 - Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is pro |
|
| April 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020. Commission File Number: 000-53805 Intellipharmaceutics International Inc. (Translation of registrant's name into English) 30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2 (Address of prin |
|
| March 30, 2020 |
EXHIBIT 4.19 Extension of Debenture Maturity Date TO Intellipharmaceutics International Inc. (the “Company”) RE: Debenture dated May 1, 2019, with an original face amount of US$1,050,000 issued by the Company to Dr. Isa Odidi and Dr. Amina Odidi (the “Debenture”) and the Maturity Date (as defined in the Debenture) of such Debenture The undersigned hereby agree that the Maturity Date of the Debentu |
|
| March 30, 2020 |
EXHIBIT 4.54 GRID PROMISSORY NOTE Dated: September 13, 2019 1. FOR VALUE RECEIVED, the undersigned, INTELLIPHARMACEUTICS CORP. (the “Borrower”), hereby promises to pay on demand to, or to the order of, Dr. Isa Odidi and Dr. Amina Odidi (the “Lenders”) the unpaid principal balance of the aggregate amount of any and all advances or any other form of financial assistance of any nature or kind whatsoe |
